Table 4. Association between BRCA1 mutations and BRCAness characteristics with clinical variables.
| |
Patients screened for BRCA1 mutations |
aCGH BRCA1 like in non-mutation carriers |
Methylation in non-mutation carriers |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No BRCA1 mutation | BRCA1 mutation | P-value | Non-BRCA1 like | BRCA1 like | P-value | No methylation | Methylated | P-value | |
| Age, median (range) |
41 (18–67) |
37 (23–68) |
0.26 |
49 (18–67) |
44 (18–75) |
0.04 |
47 (18–75) |
40 (19–75) |
0.01 |
|
Grade | |||||||||
| Grade 1/2 (%) | 35 (26) | 2 (6) | 0.02 | 25 (33) | 24 (14) | 0.01 | 30 (18) | 16 (19) | 0.80 |
| Grade 3 (%) |
102 (74) |
30 (94) |
|
51 (67) |
151 (86) |
|
137 (82) |
67 (81) |
|
|
Histology | |||||||||
| IDC (%) | 126 (98) | 20 (100) | 0.49 | 60 (97) | 127 (99) | 0.21 | 121 (99) | 61 (97) | 0.23 |
| ILC (%) |
3 (2) |
0 (0) |
|
2 (3) |
1 (1) |
|
1 (1) |
2 (3) |
|
|
T-stage | |||||||||
| T1/2 (%) | 83 (73) | 15 (54) | 0.04 | 38 (55) | 73 (52) | 0.65 | 78 (54) | 31 (50) | 0.62 |
| T3/4 (%) |
30 (27) |
13 (46) |
|
31 (45) |
68 (48) |
|
67 (46) |
31 (50) |
|
|
Nodal stage | |||||||||
| Negative (%) | 49 (43) | 14 (48) | 0.64 | 23 (34) | 70 (49) | 0.04 | 63 (43) | 30 (48) | 0.52 |
| Positive (%) |
64 (57) |
15 (52) |
|
45 (66) |
72 (51) |
|
82 (57) |
32 (52) |
|
|
Response | |||||||||
| No pCR (%) | 46 (67) | 7 (37) | 0.02 | 22 (79) | 34 (65) | 0.22 | 40 (69) | 13 (54) | 0.20 |
| pCR (%) |
23 (33) |
12 (63) |
|
6 (21) |
18 (35) |
|
18 (31) |
11 (46) |
|
|
Recurrence | |||||||||
| No relapse (%) | 60 (80) | 25 (89) | 0.27 | 42 (79) | 82 (77) | 0.71 | 86 (75) | 37 (79) | 0.66 |
| Relapse (%) | 15 (20) | 3 (11) | 11 (21) | 25 (23) | 28 (25) | 10 (21) | |||
Abbreviations: aCGH=array Comparative Genomic Hybridisation; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; pCR=pathological complete remission.